Xray Volume Imaging (Cone Beam CT) - Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00188799
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : July 16, 2015
Princess Margaret Hospital, Canada
Canadian Association of Radiation Oncology
Information provided by (Responsible Party):
University Health Network, Toronto

September 12, 2005
September 16, 2005
July 16, 2015
November 2003
Not Provided
To evaluate he feasibility of daily X-ray volume imaging during conformal radiotherapy.
Same as current
Complete list of historical versions of study NCT00188799 on Archive Site
To provide preliminary data concerning the relative utility of daily X-ray volume image matching compared to fiducial marker image matching.
Same as current
Not Provided
Not Provided
Xray Volume Imaging (Cone Beam CT) - Prostate Cancer
A Clinical Study of X-ray Volume Imaging to Evaluate the Daily Set-up Accuracy of Conformal Prostate Radiotherapy
Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostatic Neoplasms
Procedure: daily Xray volume imaging for planning radiotherapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2004
Not Provided

Inclusion Criteria:

  • Diagnosis of adenocarcinoma of the prostate
  • Patient undergoing escalated dose conformal external beam radiotherapy.
  • Patient has low or intermediate risk prognostic factors: all of PSA <21, Gleason score <8, clinical T category <T3, clinical N category 0 or X, M category 0 or X.
  • Informed consent

Exclusion Criteria:

  • No diagnosis of adenocarcinoma of the prostate
  • Patient not undergoing escalated dose conformal radiotherapy
  • Patient does not have low or intermediate risk prognostic factors
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
UHN REB 03-0483-CE
Abbott-CARO Uro-OncologicAward
Not Provided
Not Provided
Not Provided
University Health Network, Toronto
University Health Network, Toronto
  • Princess Margaret Hospital, Canada
  • Canadian Association of Radiation Oncology
Principal Investigator: Charles Catton, MD Princess Margaret Hospital, Canada
University Health Network, Toronto
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP